Armune Bioscience Financing
Armune Bioscience Inc, Corporation just released form D about $10.46 million equity financing. The date of first sale was 2015-01-08. Armune Bioscience was able to finance itself with $9.71 million. That is 92.79% of the fundraising. The total private offering amount was $10.46 million. The financing document was filed on 2016-07-12. The reason for the financing was: unspecified. The fundraising still has about $753,757 more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Armune Bioscience is based in Michigan. The company’s business is Biotechnology. The SEC form was filed by David Esposito President, CEO. The company was incorporated more than five years ago. The filler’s address is: 350 East Michigan Ave, Suite 500, Kalamazoo, Mi, Michigan, 49007. David A Esposito is the related person in the form and it has address: 350 E Michigan Ave, Ste 500, Kalamazoo, Mi, Michigan, 49007. Link to Armune Bioscience Filing: 000144037216000003.
Analysis of Armune Bioscience Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Armune Bioscience sold 92.79% of the offering. The fundraising is still open. Could this mean that the trust in Armune Bioscience is high? The average offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 215.10% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering is set at $50000. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Armune Bioscience Also
The Form D signed by David Esposito might help Armune Bioscience Inc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.